What we know — and don’t — about Trump’s Covid case

In a brief video Trump filmed before taking a helicopter flight to the hospital, he thanked Americans for their support. “I think I’m doing very well, but we’re going to make sure that things work out,” the president said.

White House physician Sean Conley said in a statement Friday afternoon that the president had been given an experimental antibody drug developed by Regeneron, which is now in late-stage clinical trials. Trump received 8 grams of the drug, the highest dose being tested in the company’s ongoing clinical trial — which could signal an aggressive treatment plan, out of an abundance of caution, or worsening symptoms.

Regeneron said Trump received the drug through a “compassionate use” program, which allows patients early access to experimental drugs with the FDA’s approval. The treatment, known as a monoclonal antibody, is a lab-made version of the antibodies that the immune system makes to ward off the virus. Regeneron said Tuesday that its antibody reduced the amount of virus in patients’ bodies in its ongoing trial, and may speed recovery.

Monoclonal antibodies like Regeneron’s are thought to work best when given early in the course of infection. This appears to be the situation with Trump, who tested positive Thursday and is showing fatigue, according to Conley’s memo, which was released before Trump left for Walter Reed. Notably, the president canceled plans to attend a phone call Friday on Covid-19 support to senior citizens, and he refrained from tweeting for 17 hours after announcing his diagnosis early Friday morning.

Late Friday, the White House released a statement from Conley announcing that Trump had started taking the antiviral drug remdesivir, made by Gilead. Originally developed to fight Ebola, it’s one of a handful of treatments that has been shown to help patients — in this case, by shortening recovery time for hospitalized patients by a few days. Data is inconclusive on whether it reduces the risk of death, however.

The FDA authorized emergency use of remdesivir in hospitalized patients in May, and evidence has shown it’s more effective the earlier it’s given in the course of a patient’s infection.

Other drugs and supplements the president is taking include a daily aspirin — often prescribed to bolster heart health — along with zinc, Vitamin D, famotidine and melatonin, each of which has been proposed as a potential Covid-19 treatment. Taken together, the cocktail suggests that Trump’s symptoms are mild to moderate, although that could change as his disease progresses.

Famotidine, a heartburn medicine also sold under the brand name Pepcid, is being tested as a coronavirus treatment on the basis of observational studies in China that suggested patients who took the drug for heartburn had a slight survival edge. But there is no direct evidence from randomized, controlled clinical trials — the gold standard for medical research — that the drug benefits people with coronavirus.

Zinc is thought to improve overall body function and protect against infection, and Vitamin D to bolster the immune system, but there is no evidence that either helps prevent or ease Covid-19 infection. Melatonin is often used as a sleep aid, and some clinical trials are investigating whether it can help reduce inflammation in coronavirus patients.

Notably, the president is not taking hydroxychloroquine, despite championing the anti-malarial drug as a Covid-19 treatment and taking it for two weeks in May after a possible virus exposure. Multiple trials have shown it to have no clinical benefit for Covid-19. Trump was closely monitored when he took the drug in spring in case he developed an irregular heart condition, a known side effect, his physician said at the time.

There’s no way to know how long Trump will be sick, or how vigorously he will be able to campaign in final days or weeks before the election. Covid-19 is notorious for its ability to attack multiple parts of the body, which can make the disease look very different from one patient to the next. It sometimes causes long-term health effects that can take months to recover from, and in some cases, can leave lasting damage to vital organs.

Here are some of the big unanswered questions about Trump’s case:

When was the president exposed?
It may be impossible to know. The National Institutes of Health says it can take up to two weeks for Covid-19 to be detected, with a median incubation period of four or five days. Speculation has focused on senior adviser Hope Hicks, who was diagnosed with the virus and traveled with Trump to the presidential debate in Cleveland on Tuesday and accompanied him to a campaign rally in Minnesota on Wednesday night.

Trump disclosed his condition early Friday morning, and the New York Times reported he appeared lethargic during an appearance at his Bedminster, N.J., club Thursday. So it’s possible the exposure could have happened earlier this week, when he campaigned in Pennsylvania, or even before then.

Did the White House have effective safety measures?
The White House hasn’t said how it screens staff and visitors, and Trump’s campaign has hosted large rallies with packed crowds of largely unmasked people. The rallies have mostly been held outdoors, where the risk of virus spread is lower, but his campaign held an indoor rally in Nevada about three weeks ago in defiance of state restrictions, and another in Duluth, Minn., on Wednesday.

The administration has in the past relied on a rapid test from Abbott Laboratories that can produce results in as soon as 15 minutes. But the test has been shown to have high error rates, and it’s likely that the White House confirmed the president and first lady’s infections with additional lab-based testing. The White House declined to comment on testing procedures.

Even the best tests don’t catch every case, though. Public health experts say there’s no substitute for wearing face coverings and observing social distancing — precautions Trump has frequently flouted.

What other drugs might he take?
Only a handful of treatments have been shown to help patients. Remdesivir is one; a decades-old steroid called dexamethason is another. U.K. scientists reported in June that it reduced the risk of death for severely ill patients. But the drug, which quiets the immune system, could backfire in mild or moderately ill patients.

The Trump administration has also aggressively promoted the use of antibody-rich blood plasma from coronavirus survivors. It’s been used in the past to treat diseases ranging from Ebola to diphtheria, with mixed results. There’s no clear evidence it helps those ill with Covid-19, and an expert panel advising the government says it should not be considered standard of care. The FDA issued an emergency use authorization for the treatment in late August over the objections of top federal scientists.

Could there be long-term effects?
There’s a growing population of patients who haven’t fully recovered from the coronavirus months after first experiencing symptoms. Many of these “long haulers” had mild or moderate symptoms that sometimes didn’t require hospitalization.

Common symptoms that linger over time include fatigue, a cough, shortness of breath, headaches, joint pain and in some cases, damage to the heart, lungs or brain. The difficulty of predicting outcomes has led scientists to study patients who had related viruses like SARS. The Mayo Clinic notes many who recovered went on to develop chronic fatigue syndrome, a disorder that worsens with physical or mental activity but doesn’t improve with rest.